Evaluation of 68-GaNOTA-Anti-HER2 VHH1 Uptake in Brain Metastasis of Cancer Patients

NCT03331601 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma
Receptor, ErbB-2

Interventions

DRUG: 68GaNOTA-Anti-HER2 VHH1

Sponsor

Universitair Ziekenhuis Brussel